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Abstract
Background: The sodium/iodide symporter (NIS) is a membrane glycoprotein mediating active
iodide uptake in the thyroid gland and is the molecular basis for radioiodide imaging and therapeutic
ablation of thyroid carcinomas. NIS is expressed in the lactating mammary gland and in many human
breast tumors, raising interest in similar use for diagnosis and treatment. However, few human
breast tumors have clinically evident iodide uptake ability. We previously identified PI3K signaling
as important in NIS upregulation in transgenic mouse models of breast cancer, and the PI3K
pathway is commonly activated in human breast cancer.
Methods: NIS expression, subcellular localization, and function were analyzed in MCF-7 human
breast cancer cells and MCF-7 cells stably or transiently expressing PI3K p110alpha subunit using
Western blot of whole cell lysate, cell surface biotinylation Western blot and immunofluorescence,
and radioiodide uptake assay, respectively. NIS localization was determined in a human breast
cancer tissue microarray using immunohistochemical staining (IHC) and was correlated with pre-
existing pAkt IHC data. Statistical analysis consisted of Student's t-test (in vitro studies) or Fisher's
Exact Test (in vivo correlational studies).
Results: In this study, we demonstrate that PI3K activation in MCF-7 human mammary carcinoma
cells leads to expression of underglycosylated NIS lacking cell surface trafficking necessary for
iodide uptake ability. PI3K activation also appears to interfere with cell surface trafficking of
exogenous NIS as well as all-trans retinoic acid-induced endogenous NIS. A correlation between
NIS expression and upregulation of PI3K signaling was found in a human breast cancer tissue
microarray.
Conclusion: Thus, the PI3K pathway likely plays a major role in the discordance between NIS
expression and iodide uptake in breast cancer patients. Further study is warranted to realize the
application of NIS-mediated radioiodide ablation in breast cancer.
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Background
Breast cancer is one of the most common cancers in
women in North America, where incidence is highest in
the world [1]. In the United States, more than 200,000
newly diagnosed cases were estimated in the year 2005.
While treatment with surgery, chemotherapy, hormonal
and radiation therapy, and antibodies targeting the Her-2/
neu growth promoting protein have slowed disease pro-
gression or resulted in remission in many patients, meta-
static disease still causes death in the majority of affected
patients within 5 years of diagnosis. Thus, continued dis-
covery of novel methods of detecting and treating residual
and metastatic breast cancer are of extremely high impor-
tance.
The sodium/iodide symporter (NIS) is a plasma mem-
brane glycoprotein serving as the molecular basis for
iodide accumulation in the thyroid gland, where it medi-
ates active uptake of iodide from the bloodstream for
incorporation into thyroid hormones [2]. Radioiodine is
routinely administered to patients for the diagnosis and
treatment of thyroid carcinomas, resulting in a 10-year
survival rate of greater than 90% [3,4].
NIS is also expressed in the lactating mammary gland,
where it facilitates uptake of iodide from the maternal
bloodstream into milk for utilization by the developing
neonatal thyroid gland [5,6]. While NIS has been detected
in approximately 80% of human breast cancers using
immunohistochemical staining [7], few tumors have clin-
ically evident iodide uptake ability. In one study,
although 24 out of 25 breast cancer patients had detecta-
ble NIS mRNA expression in their primary tumors, posi-
tive radionuclide uptake was only noted in four of the
tumors (17%) and was correlated with NIS mRNA expres-
sion level [8]. A second study demonstrated that only 25%
(2/8) of breast cancer metastases expressing NIS protein
had clinically evident radionuclide uptake [9]. NIS-medi-
ated radionuclide imaging and therapy has exciting poten-
tial as a safe and effective method of breast cancer
diagnosis and treatment, and delineating factors underly-
ing the discordance between NIS expression and function
is critical in moving this modality into the practical realm.
To achieve this aim, mechanisms of NIS regulation in
breast cancer must be uncovered.
We previously found that phosphatidylinositol-3 kinase
(PI3K) and cAMP signaling pathways were associated with
NIS expression in transgenic mouse models of breast can-
cer [10]. However, cAMP alone was not sufficient to
induce NIS protein expression in cultured MCF-7 human
mammary carcinoma cells. Our current study was to eval-
uate the role of PI3K signaling in NIS expression, traffick-
ing and iodide uptake ability in MCF-7 cells and in
human breast tumors, as activating mutations of the PI3K
p110α subunit are frequent in human breast cancers [11]
and cell lines [12]. We found that stable or transient acti-
vation of PI3K p110α in MCF-7 cells increases underglyc-
osylated NIS protein levels with impairment of NIS cell
surface trafficking, which is required for iodide uptake
activity. PI3K activation also interferes with cell surface
trafficking and function of all-trans  retinoic acid and
hydrocortisone (tRAH) induced endogenous NIS as well
as transiently expressed exogenous Flag-tagged NIS.
Finally, an association was found between PI3K activation
and NIS expression in human breast tumor tissues.
Methods
Cell culture
MCF-7 cells were maintained in medium consisting of
equal parts phenol red-containing DMEM and Ham's F12,
10% fetal bovine serum (FBS) and 1% penicillin/strepto-
mycin (Invitrogen, Carlsbad, CA). Two MCF-7 stable
clones expressing PI3K p110αCAAX were generated in the
laboratory of Dr. James McCubrey at East Carolina Uni-
versity [13] and maintained in 89% RPMI (Invitrogen,
Carlsbad, CA), 10% FBS, and 1% penicillin/streptomycin.
In experiments requiring treatment with 1 μM trans-retin-
oic acid and 0.1 μM hydrocortisone (tRAH; Sigma, St.
Louis, MO), both experimental and control groups of
MCF-7 and MCF-7/PI3K p110αCAAX cells were transferred
to medium composed of equal parts DMEM and Ham's
F12, 5% charcoal-stripped FBS and 1% penicillin/strepto-
mycin.
DNA constructs
PI3K p110αCAAX was cloned into the BamHI site in the
pcDNA3 vector. Flag-tagged human NIS open reading
frame was cloned into the pcDNA3 vector as described in
Zhang et al. [14]. Fugene6 reagent (Roche, Alameda, CA)
was used for transient transfection according to the man-
ufacturer's protocol. Co-transfection of a GFP expression
plasmid was used to assess transfection efficiency.
Cell surface biotinylation
Cell surface NIS expression was determined as described
in Vadysirisack et al. [15]. Cells were surface biotinylated
and lysed, followed by avidin pull-down using 5 mg of
total cell lysate. Pulled-down biotinylated surface protein
derived from MCF-7/PI3K p110αCAAX cells and MCF-7
cells treated with tRAH for 48 hours [16] was used for
Western Blot as described below.
Western blot analysis
Western blot was performed as described in Jhiang et al.
[17] using 100 μg of total cell lysates or membrane-
enriched fraction (after removal of nucleus and cytosol)
for total NIS, β-actin or Na+K+ATPase detection, or the
pulled-down biotinylated surface protein, as described
above, for surface NIS and Na+K+ATPase detection. AktBMC Cancer 2007, 7:137 http://www.biomedcentral.com/1471-2407/7/137
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and pAkt Ser473 levels were assessed using 100 μg of
whole cell lysate. Experiments utilized anti-hNIS antibody
(#331, 1:1000), anti-actin antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA; 1:200), anti-Akt and anti-pAkt
Ser473 antibody (Cell Signaling Technology, Danvers,
MA; 1:250) or anti-Na+K+ATPase antibody (Santa Cruz
Biotechnology, Santa Cruz, CA; 1:1000). Secondary anti-
bodies were anti-rabbit IgG conjugated to horseradish
peroxidase for NIS, actin, Akt and pAkt Western blot (GE
Healthcare Bio-Sciences Corp, Piscataway, NJ; 1:4000) or
anti-mouse IgG conjugated to horseradish peroxidase for
Na+/K+ATPase Western blot (Cell Signaling Technology,
Danvers, MA; 1:4000). NIS antibody specificity was veri-
fied by PNGase F deglycosylation of NIS protein to a sole
50 kDa band, the molecular weight of underglycosylated
NIS. Densitometry was performed by scanning with the
Scion Image program (Scion Corp., Frederick, Md.).
Immunofluorescence
NIS and Flag immunofluorescence were performed essen-
tially as described in Marsee et al. [18]. Briefly parental
MCF-7 cells and MCF-7/PI3K p110αCAAX stable clones
were seeded in 4-well chamber slides. Forty-eight hours
after Flag-hNIS or empty vector transfection or tRAH treat-
ment (when applicable), cells were fixed using 1% para-
formaldehyde in PBS and labeled with anti-NIS antibody
(#331; 1:1000) or anti-Flag M2 monoclonal antibody
(Sigma, St. Louis, MO; 1:750), followed by incubation
with CyTM3-conjugated affinipure F(ab')2 fragment don-
key anti-rabbit IgG (1:1400) for NIS immunofluorescence
or anti-mouse IgG (Jackson ImmunoResearch Laborato-
ries, West Grove, PA; 1:500) for Flag immunofluores-
cence. DAPI nuclear stain (Invitrogen, Carlsbad, CA) was
applied before mounting and coverslipping. Secondary
antibody only negative controls were included in the
experiments. Images were obtained at 63× magnification
using a Leica TCS SP2 AOBS Confocal Laser Scanning
Microscope in The Ohio State University College of Veter-
inary Medicine.
Radioactive iodide uptake assay
RAIU was performed as described in La Perle et al. [19]
using MCF-7 or MCF-7/PI3K p110αCAAX cells after forty-
eight hours of tRAH treatment, Flag-hNIS or activated
PI3K p110αCAAX transient transfection (when applicable).
In experiments involving transfection of MCF-7 cells and
subsequent treatment with tRAH, the transfection time
was set at 6 hours, followed by medium change and addi-
tion of tRAH for 42 hours. After incubation with 125I,
washing and cell lysis, the supernatant was counted in a γ-
radiation counter. Values were recorded in counts per
minute (cpm) per microgram of DNA. Assays were per-
formed in triplicate.
Immunohistochemistry
Immunohistochemical staining technique was performed
as described in Knostman et al [10] with the following
modifications. A paraffin-embedded formalin-fixed
human breast cancer tissue microarray consisted of 2 mm
punches from 50 patient samples sectioned to 4 μm thick-
ness and affixed to glass slides. Slides were incubated with
rabbit polyclonal anti-human NIS primary antibody
(#331; 1:500) followed by HRP-conjugated goat anti-rab-
bit IgG secondary antibody (Bio-Rad, Hercules, CA;
1:250) and chromogen DAB detection (Dako, Carpinte-
ria, CA). Immunostaining for pAkt was performed in The
Ohio State University Department of Pathology using
mouse monoclonal anti-pAktSer473 antibody (Cell Signal-
ing Technology, Danvers, MA; 1:100). Thirty-three of the
36 tissues in the array had suitable integrity for interpreta-
tion of NIS positivity and pAkt expression and were
included in the statistical analyses.
Statistical analysis
Statistical analysis consisted of Student's t-test (in vitro
studies) or Fisher's Exact Test (in vivo correlational stud-
ies) and was performed using GraphPad software. Only
breast cancer tissue punches available for NIS, pAkt and
PTEN immunohistochemical staining were used in statis-
tical analyses. Additional comparison of NIS expression
and estrogen receptor, progesterone receptor and Her-2/
neu expression was performed, but no statistical relation-
ship was evident.
Results
The importance of PI3K signaling in NIS regulation was
studied using MCF-7 human mammary carcinoma cells,
which are the only immortalized breast cancer cells with
inducible NIS expression and function [20]. While NIS
protein was not detectable in untreated MCF-7 cells, it was
markedly induced by all-trans retinoic acid combined with
hydrocortisone (tRAH) [16] as the glycosylated 86 kDa
form (Figure 1A). In contrast, only the underglycosylated
50 kDa NIS form was present in MCF-7 cells stably
expressing activated PI3K p110αCAAX. Cell surface NIS
protein was detectable in MCF-7 cells treated with tRAH,
but not in the MCF-7 cells stably expressing PI3K
p110αCAAX (Figure 1B). NIS immunofluorescence was per-
formed to further assess the effect of PI3K activation on
NIS subcellular localization in MCF-7 cells. While intense
cell border NIS protein was evident in the tRAH-treated
MCF-7 cells (arrows, left panel, Figure 1C) and sparsely
located in the perinuclear area, it was not apparent in the
MCF-7/PI3K p110αCAAX cells, where NIS appeared dis-
persed throughout the intracellular compartment (right
panel, Figure 1C).
PI3K activation also appears to interfere with the ability of
tRAH to induce glycosylated NIS protein expression. AsBMC Cancer 2007, 7:137 http://www.biomedcentral.com/1471-2407/7/137
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PI3K activation induces underglycosylated intracellular NIS protein expression in MCF-7 cells Figure 1
PI3K activation induces underglycosylated intracellular NIS protein expression in MCF-7 cells. (A) immunoblotting of mem-
brane-enriched lysates from MCF-7 cells with and without tRAH treatment and MCF-7/PI3K p110αCAAX stable clones using 
human NIS (hNIS) antibody. The specificity of NIS antibody was confirmed by conversion of the 86 kDa NIS band to a single 50 
kDa band upon PNGase F deglycosylation (data not shown). Faint non-specific bands of 60 and 70 kDa are present. PI3K acti-
vation was assessed by total and phospho-Akt immunoblotting of total cell lysates. Actin was used as a loading control. (B) 
Immunoblotting of the surface protein fraction from MCF-7 cells treated with tRAH and MCF-7/PI3K p110αCAAX stable clones 
using hNIS antibody. The surface fraction was isolated by cell surface biotinylation and avidin pull-down. Na+/K+ATPase was 
used as a loading control. (C) tRAH-treated MCF-7 cells and MCF-7/PI3K p110αCAAX cells were labeled with hNIS antibody 
followed by CyTM3-conjugated secondary antibody (red color) and DAPI nuclear stain (blue) for immunofluorescent micros-
copy. Parental MCF-7 cells and secondary antibody only controls were utilized, but are not shown. Magnification = 63×.BMC Cancer 2007, 7:137 http://www.biomedcentral.com/1471-2407/7/137
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Stable or acute PI3K activation decreases tRAH-induced glycosylated NIS protein expression and NIS-mediated radioactive  iodide uptake in MCF-7 cells Figure 2
Stable or acute PI3K activation decreases tRAH-induced glycosylated NIS protein expression and NIS-mediated radioactive 
iodide uptake in MCF-7 cells. (A) 48 hours of tRAH treatment induces fully glycosylated NIS protein in MCF-7 cells transiently 
transfected with empty vector. Underglycosylated 50 kDa NIS is dominant in MCF-7/PI3K p110αCAAX cells, which minimally 
respond to tRAH treatment. Transient expression of PI3K p110αCAAX also induces underglycosylated NIS protein expression 
with a modest decrease in the tRAH-induced fully glycosylated NIS form. (B) tRAH treatment cannot induce NIS function in 
MCF-7/PI3K p110αCAAX cells. A small increase in basal NIS-mediated radioactive iodide uptake is noted in MCF-7/PI3K 
p110αCAAX stable clones versus parental MCF-7 cells. Cells were treated with tRAH for 48 hours followed by 125I uptake assay. 
Perchlorate (ClO4
-) is a specific inhibitor of NIS function. ***p < .0001. (C) Acute expression of activated PI3K p110α 
decreases tRAH-induced NIS function in MCF-7 cells. A modest increase in basal NIS-mediated radioactive iodide uptake is 
present in MCF-7 cells transiently transfected with PI3K p110αCAAX versus vector-only controls. Cells were transiently trans-
fected with pcDNA3/PI3K p110αCAAX or empty vector for 6 hours, and then treated with tRAH for 42 hours prior to 125I 
uptake assay. *p < .05.BMC Cancer 2007, 7:137 http://www.biomedcentral.com/1471-2407/7/137
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PI3K activation interferes with cell surface trafficking and radioiodide uptake conferred by exogenous Flag-tagged hNIS gene  expression Figure 3
PI3K activation interferes with cell surface trafficking and radioiodide uptake conferred by exogenous Flag-tagged hNIS gene 
expression. (A) MCF-7 and MCF-7/PI3K p110αCAAX cells were transiently transfected with pcDNA3/Flag-hNIS and subjected 
to Flag immunofluorescence 48 hours later. While Flag-hNIS is detectable on the cell surface in parental MCF-7 cells (arrows), 
it is retained intracellularly in MCF-7/PI3K p110αCAAX cells. Magnification = 63×. (B) MCF-7 and MCF-7/PI3K p110αCAAX cells 
were transiently transfected with pcDNA3/Flag-hNIS and subjected to 125I uptake assay 48 hours later. A nearly 4-fold increase 
in 125I uptake resulting from exogenous NIS expression is present in parental MCF-7 cells as compared to MCF-7/PI3K 
p110αCAAX. **p < .001.BMC Cancer 2007, 7:137 http://www.biomedcentral.com/1471-2407/7/137
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shown in Figure 2A, while abundant glycosylated NIS pro-
tein was induced by tRAH treatment in parental MCF-7
cells (lane 1 vs. lane 2), underglycosylated 50 kDa NIS was
the dominant form in MCF-7/PI3K p110αCAAX  cells,
which negligibly responded to tRAH treatment with glyc-
osylated NIS protein (lane 3 vs. lane 4). Transient expres-
sion of PI3K p110αCAAX  also induced the
underglycosylated 50 kDa NIS form (lane 1 vs. lane 5),
and responsiveness to tRAH treatment with glycosylated
NIS protein was decreased by approximately 45% (lane 2
vs. lane 6) even though the transfection efficiency was
only 20–25%. Interestingly, tRAH treatment slightly
decreased the overall level of NIS protein in MCF-7/PI3K
p110αCAAX cells.
MCF-7/PI3K p110αCAAX cells initially had modest basal
iodide uptake ability, as published in our previous study
[10], but most of this function was lost over cell passage
even though NIS protein remained detectable. Radioio-
dide uptake ability in our current study correlated well
NIS is expressed in 80% of human breast tumors in a tissue microarray with primarily intracellular localization and positive cor- relation with pAkt expression Figure 4
NIS is expressed in 80% of human breast tumors in a tissue microarray with primarily intracellular localization and positive cor-
relation with pAkt expression. (A-C) NIS immunohistochemical staining in three representative breast cancer specimens. (A) 
NIS-negative breast tumor. (B) Breast tumor with intracellular NIS localization. (C) Breast tumor with both intracellular and 
plasma membrane-localized NIS protein (arrows). (D-F) Immunohistochemical staining for pAkt in the three breast tumors 
shown in A-C. (G-I) H & E staining demonstrating the histopathology of the three breast tumors shown in A-C. Bar = 20 μM.BMC Cancer 2007, 7:137 http://www.biomedcentral.com/1471-2407/7/137
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with fully glycosylated (surface) NIS protein levels. The
stably transfected MCF-7/PI3K p110αCAAX cells had mini-
mally increased NIS-mediated radioiodide uptake over
parental MCF-7 cells and did not significantly respond to
tRAH treatment (Figure 2B). Transient transfection of acti-
vated PI3K p110αCAAX in parental MCF-7 cells modestly
increased NIS-mediated radioiodide uptake over empty
vector-transfected controls but decreased tRAH-induced
radioiodide uptake activity (Figure 2C).
A similar inhibitory effect of PI3K activation on NIS sur-
face trafficking and function was observed upon forced
expression of exogenous NIS. Immunofluorescence for
exogenous Flag-tagged NIS protein demonstrated that
Flag-NIS cell surface trafficking was largely inhibited in
MCF-7/PI3K p110αCAAX  cells as compared to parental
MCF-7 cells (Figure 3A). Additionally, radioiodide uptake
activity conferred by transient transfection of exogenous
Flag-NIS was decreased by 4-fold in MCF-7/PI3K
p110αCAAX cells versus parental MCF-7 cells (Figure 3B).
Thus, cell surface trafficking of both endogenous and
exogenous NIS were decreased by PI3K activation.
To determine whether PI3K upregulation plays a role in
the discordance between the increase in NIS expression
and the absence of radioiodide uptake activity in human
breast tumors, we evaluated a human breast cancer tissue
microarray for NIS expression and localization using
immunohistochemistry. This array consisted of randomly
selected breast tissues from patients at The Ohio State
University Medical Center with a diagnosis of breast carci-
noma during the years 1992–1994. Tumors were 51% ER-
positive, 57% PR-positive, 53% Her-2/neu-positive, and
27% with loss of PTEN tumor suppressor, each of which
had no statistical correlation with NIS expression. All
tumor specimens were primary, although 29% of the
patients also had local lymph node metastases. None had
known distant metastases at the time of biopsy. Patients
had an average age of 42.26 years and were 89% Cauca-
sian and 11% African-American.
We correlated NIS expression/localization with the pres-
ence of PI3K activation as indicated by phosphorylation
and nuclear translocation of Akt, which is commonly used
to estimate PI3K pathway activation. Similar to previously
published data, only 20% of tumors were NIS-negative
(Figure 4A). Overall, 58% of tumors had primarily intrac-
ellular NIS expression (Figure 4B), while 22% had some
degree of plasma membrane NIS expression (Figure 4C).
NIS-positive tumors were three times more likely than
NIS-negative tumors to have PI3K activation as indicated
by Akt phosphorylation (Table 1 and Figures 4A–C versus
4D–F). Interestingly, all tumors with loss of the PTEN
(PI3K antagonist) and concomitant pAkt expression had
marked intracellular NIS expression without notable cell
surface NIS expression.
Discussion
This study is the first to uncover a potential explanation
for the discordance between NIS expression and iodide
uptake ability in human breast cancers, a roadblock to
widespread application of NIS-mediated radioiodide
imaging and ablation of residual and metastatic tumors.
We showed that both transient and chronic PI3K activa-
tion increase underglycosylated NIS protein levels but
impair NIS cell surface trafficking, thus accounting for the
absence of NIS-mediated radioiodide uptake activity. NIS
expression and intracellular localization were also associ-
ated with pAkt expression in human breast cancer tissues.
Our study suggests that the increased intracellular NIS
protein in human breast cancer specimens [7] is likely a
consequence of PI3K activation.
Many human breast cancers have PI3K activation as a con-
sequence of Her-2/neu or Src oncogene expression [21],
or by activating mutations of the PI3K p110α subunit
[11], any of which could lead to NIS expression. In our
breast cancer tissue microarray, PI3K activation might be
explained by Her-2/neu expression in 48% of the pAkt-
positive tumors or by loss of PTEN in 19% of pAkt-posi-
tive tumors. Activating point mutation E545K in the heli-
cal domain of PI3K p110α has been described in many
cultured breast cancer cells, including MCF-7 [12]. In our
study, both chronic and transient PI3K p110α overexpres-
sion resulted in 2–3 fold greater pAkt protein levels than
found in parental MCF-7 cells.
The lack of NIS protein glycosylation in PI3K p110αCAAX-
expressing MCF-7 cells is consistent with impairment of
processing for NIS cell surface trafficking. Membrane glyc-
Table 1: Correlation of NIS expression and localization with Akt activation and localization
Tumor classification nuclear pAkt any pAkt any pAkt +loss of PTEN
n% n % n %
NIS-negative tumors 2/7 28 2/7 28* 0/7 0
NIS-positive tumors 16/26 62 19/26 73* 4/25 16
NIS intracellular (only) 12/19 63 14/19 74 4/18 22
NIS plasma membrane (any) 4/7 57 5/7 71 0/7 0
* p < .05BMC Cancer 2007, 7:137 http://www.biomedcentral.com/1471-2407/7/137
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oproteins are processed by glycosylation beginning in the
endoplasmic reticulum and Golgi apparatus with trans-
port using machinery such as the AP-1B adaptor complex
and clathrin-coated vesicles and final transport to the cell
surface by carrier vesicles [22]. While it is not currently
known how PI3K activation interferes with NIS cell sur-
face trafficking, it is known that one subtype of PI3K inter-
acts with clathrin [23].
It has been shown that abolishing three glycosylation sites
in human NIS resulted in a 50 kDa NIS protein with
decreased NIS activity after exogenous delivery into COS
cells [24]. The fact that this mutant still had 50% of wild-
type iodide uptake ability indicates that some NIS protein
was able to reach to the cell surface. However, it was
unclear whether the decrease in radioiodide uptake was
due to less efficient cell surface trafficking or to a decrease
in NIS activity. We interpret the lack of NIS glycosylation
in our MCF-7 model to be a consequence of protein reten-
tion at a pre-glycosylation stage rather than a cause of traf-
ficking failure. However, we cannot exclude that a lack of
glycosylation itself might impair trafficking and function.
In our current study, tRAH-responsive NIS induction was
nearly abolished in MCF-7/PI3K p110αCAAX  cells and
reduced in parental MCF-7 cells transiently transfected
with PI3K p110αCAAX. The greater inhibition of NIS cell
surface trafficking and function in PI3K-overexpressing
stable clones vs. PI3K-transfected MCF-7 cells could be
related to chronicity of PI3K activation, which is a likely
scenario in human breast cancer. Additionally, transient
transfection efficiency is only 25–30% in MCF-7 cells.
In summary, this study advances our knowledge of NIS
regulation in breast cancer by demonstrating that PI3K
signaling increases underglycosylated NIS protein levels
without an increase in NIS-mediated radioiodide uptake
activity due to impairment in NIS cell surface trafficking.
Because many oncogenes in human breast cancer upregu-
late PI3K signaling, and PI3K somatic mutation was fre-
quently detected in human breast cancers, this pathway
could realistically account for the high intracellular NIS
expression and lack of radioiodide uptake in most human
breast cancers. The fact that PI3K signaling appears to
have differential effects on NIS expression in the breast
versus thyroid suggests that a strategy may be developed
to selectively increase NIS expression in breast tissue. Fur-
ther investigation into the mechanism(s) of impairment
of NIS cell surface trafficking by PI3K will be critical in
realizing the application of NIS-mediated radioiodide
imaging and ablation in breast cancer.
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